Vice President, Research and Preclinical Development
Fabrice Piu, Ph.D., joined Otonomy at its inception in August 2008 as Senior Director of Research and Non-Clinical Development and has served as our Vice President, Research and Preclinical Development since January 2013. He has more than twenty years of drug research and development experience primarily in the field of neuroscience. Previously, he held various management positions at ACADIA Pharmaceuticals, including Director of Chemical Genomics, where he helped support the development of Nuplazid® (pimavanserin), an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s Disease. Dr. Piu was a post-doctoral fellow in the Pharmacology Department at the University of California, San Diego. He holds a Ph.D. in Molecular and Cellular Biology from Ecole Normale Superieure and University of Lyon, France, a Master’s degree in Genetics and Immunology and Bachelor’s degrees in Molecular and Cellular Biology, and Biochemistry, from the University of Lyon.